Bioprogress is a stock I have been in and out of quite a few times since it floated in May but not much mention here on the Investors' Room. Does anyone else follow this stock. I see it is up 1.5p today and a few good buyers seem to have appeared.

Very true words kivver, it dont make sense, glad i bought into SEO also.

BPRG's trading statement said that they would announce deals taht would affect 2005 in the next few weeks, that was on 18/11/04. No news has given weakness to the stock, but axm will announce re the soluleaves deal in china by the end of the month

Chart looks like good support forming. RSI looking interesting

Can you expand on that Jumpin, whys is that because the price has been reasonably stable for a while?

More or less and in narrow range so that is indicating a big move shortly, a close above 70p on good vol would be sign for further gains

Thanks, ets hope so I for one would like to see a return to 1.00 then i'll be back in blue...

AdieH,, I would like to see this share above 100p but I think it is going to bounce around for a little longer yet and then meet a little resistance again at 90p. We will see, but up from here is good enough for me for a while.

I see nasdaq was up 3% yesterday and now up 5.58% so far today. Two day consecutive rise (although very small) on LSE - maybe things are starting to change for BPRG. News on damages from SEO should see it rocket again.

Looking good for a trading breakout. Bought twice already this morning and going to have more now. Dont miss it.

cheers GF.

Added another tranche at 68.6p.

cheers GF.

Looking better, but would like a little more movement. Was worrying about death duties, now having to worry about CGs.













Like hell!

LOL Fred. Should crack on up over the next few days.

cheers GF.

I thought BPRG posters would like to read this European Marketing brochure published by them. Clearly there is a lot of potential for their products!

.........................

A Revolution in Progress

BioProgress technologies are bringing a revolution in the way that the pharmaceutical industry manufactures and presents products to the consumer.

The discovery and development of XGel film Technologies by BioProgress is causing a revolution in the product
offerings and manufacturing methods now available to the pharmaceutical industry.

BioProgress will bring its customers a marketing edge in products suited to the needs and demands of consumers in
the 21st Century. The unique BioProgress technologies enable new product penetrations and offer a revolution in the manufacturing and presentation of pharmaceuticals and healthcare products.

Our Strategy Alliances and Partnerships

Our strategy is to form long-term alliances and partnerships with companies that have the skills, infrastructure, energy
and vision to turn these unique technologies into successful commercial products.

BioProgress develop complete film systems.
These comprise:
The developmement of XGelformulations.
The protection of XGel technologies by patents.
The design and commissioning of production machinery
required to turn these inventions into commercial products.

Our partners apply these technologies to their current product range or use them to develop advanced new products.
If required, BioProgress can help with the preparation of product authorisations. Production equipment can be
purchased from BioProgress or we can help with locating a licensed sub-contractor. Partners are granted marketing
rights covering film systems and formulations for geographical areas, as appropriate.

The XGelfilms are manufactured in BioProgress film casting subsidiaries. The first of these BioTec Films LLC, was acquired in March 2004 and is located in Tampa, Florida.

A revolution in pharmaceutical materials

We have developed the processes, the technology and the necessary understanding to
both dramatically enhance the appeal and performance of existing products and create
new and exciting ones.

The invention and subsequent development of the family of XGelfilm systems began in 1996.

BioProgress set out to formulate a range of films which would be turned to the needs of todays consumers. They are
animal- free, biodegradable, non-allergenic and made from ecologically sustainable resources. In particular, these film
systems provide industry with a cost-effective alternative to traditional gelatin, widely used for encapsulating liquids and powders and for coating tablets.

Gelatin is derived from animal renderings. Recent BSE publicity has highlighted the potential dangers of using such
materials in the health-care industry. Increasingly, consumers, environmentalists, vegetarians and ethnic and groups
have become aware of and concerned about the derivation of gelatin.

Consequently, pharmaceutical and healthcare companies have been assessing the risks of relying on gelatin in the
future and have been actively looking for viable alternatives.

XGelFilms are capable of meeting the individual needs of our customers.

XGelfilm formulations can be adapted to be soluble in either hot or cold water, and to meet specific solubility
and dissolution requirements.

XGelfilms can be coloured and overprinted to make products individual in appearance.

XGelfilms can have a polished and bright appearance.

XGelfilms are suitable for vegetarians and have accreditation with various religious groups, including Jewish
and Muslim faiths.

XGelfilms are suited to high-speed manufacturing and require minimal post-production drying or finishing.

XGel- intellectual property

All intellectual property associated with XGelfilm systems is covered by patents throughout the world.
This protects both the company and its growing list of licensed partners in the commercial development of
products and new markets.

A revolution in applications

Its strength and flexibility mean that XGelhas growing list of applications in the pharmaceutical, healthcare and dietary supplement industries, and also for other
non-ingestible products.

SWOLLOSWOLLOis a complete production system for manufacturing soft-gel liquid-fill capsules.
The system is based on non-gelatin XGelfilm, a strong, effective and stable barrier. The films
are produced from animal-free and ecologically sustainable resources. They are therefore suitable
for vegetarians and ethnic groups unable to consume gelatin.
The XGelfilm is supplied to the manufacturer by BioProgress as bulk rolls which can be coloured
and printed if required. SWOLLOproduction machines are designed for high output and rapid
changeover. They can be readily incorporated within customers existing manufacturing facilities,
requiring no special production or environmental controls and taking up as little space as two
standard tablet presses.
This revolutionary method of SWOLLOsoft-gel encapsulation is in sharp contrast to traditional
gelatin encapsulation methods, where little has changed over the past 50 years. Gelatin requires
special mixing equipment to generate the ribbon used for encapsulation. Production has to be
continuous and capsules require tumble-drying before they are hard enough to be collected on trays
which are then dried in special ovens for up to 48 hours. Such specialist and expensive plant exists
only in a handful of sites throughout the world these producers have the market on the production
of soft-gel capsules. By contrast, SWOLLOproduction is fast, clean and efficient. The capsules
are produced on multi-station formers. Output are high and the process can be stopped and started,
as required. Capsules need no further drying and are ready for final inspection and packing.
The SWOLLOproduction systems have been designed for fast changeover and easy cleaning.
At last the possibility for manufacturers to produce their own non-gelatin soft gels!

SEPTUMSEPTUMis at the cutting edge of multi-chamber technology. The system is related to SWOLLOtechnology and allows manufacturers to incorporate two fills within a single soft capsule. Variations in
XGelformulation can provide differential release of active ingredients.
Capsule fills could include combinations of liquids, suspensions, beadlets or dry powders. This
revolutionary technology opens the way for a new generation of delivery systems, which could extend
the lifecycle of existing pharmaceutical products and provide innovation for new ones.

NROBENROBEis a powder compaction and tableting technology.
Powders can be lightly compressed and then wrapped in XGelfilm. There are many revolutionary
advantages in using this system as there is no need to include the usual quantities or number of tableting
excipients., This reduces the formulation cost, cuts down the dispensing and mixing operations required
and potentially results in a smaller final dosage form.
Disintegration and dissolution times will potentially improve from those obtained with standard compressed
Tablets, and product stability is improved over some two-piece capsules. Film or sugar-coating is unnecessary
as the XGelfilm provides an effective and attractive coating. This saves further processing and production
costs by cutting out coating and polishing operations and equipment. The XGelfilm can be supplied
coloured and printed.
NROBEopens up the possibilities of new and more effective formulations with this revolutionary delivery
system.

TABWRAPTABWRAPis a revolution in quality high-speed tablet coating production. Standard compressed tablet
cores are overwrapped with XGelfilm in a continuous process. There should be no need for extensive
tablet reformulation or product registration.
XGelfilm can be supplied coloured and overprinted, or the final wrapped tablets may be overprinted as
part of the TABWRAPprocess, if required, to provide further brand identity. The film can also be made
to adopt any underlying tablet embossing. Attractive two-colour tablets are readily produced by using
different coloured films for the top and for the bottom wrap. Manufacturers have full control over their
production and no longer have to ship to a gelatin toll manufacturer to have their product coated. Additionally,
TABWRAPcan be used to replace single colour spray-coated products, enabling manufacturers to save
on overheasdsad capital equipment costs associated with film or sugar-coating. A high quality tablet finish is
produced in a fast, continuous process. TABWRAPis flexible and does not have to conform to the batch
loadings of tablet coaters.
TABWRAPproduction equipment is designed for fast and easy cleaning and this makes TABWRAPtechnology the ideal solution for both long- and short-run tablet production.

SOLULEAVESSOLULEAVESis a revolutionary delivery system for flavours or active pharmaceutical ingredients.
Special formulations of XGelfilm incorporate the ingredients which are instantly released when the film
rapidly dissolves upon contact with saliva in the mouth. This system has already been successfully applied
to flavour-release products such as mouth fresheners, confectionery and vitamin products.
The oral cavity provides absorption sites in both the sublingual and buccal mucosa. SOLULEAVEStechnology can be used to deliver active ingredients to these sites efficiently and in a pleasant and easily
portable form. Water is not required for administration. Other interesting applications of the SOLULEAVESinclude the use on unconscious or comatose patients, small children and the elderly who struggle with
conventional tablets. The SOLULEAVEStechnology can even be adapted for veterinary applications.

WAFERTABWAFERTABis a patented delivery system that uses a unique process to prepare drug-loaded medication
in thin films which can be used in topical or oral application. Active ingredients are incorporated into the film
after casting. In addition, layers of film can be built up. The final film may then be cut into shape or, for thicker
laminates, punched into a tablet format. This revolutionary delivery system opens up exciting formulation
possibilities. For example, different layers may be composed of different films to provide different release rates
with different actives the formulation possibilities are endless!

FOAMBURSTFOAMBURSTis a new patent granted in September 2004 which is for capsules made of foamed film.
Gas is blown into the film during production, resulting in a film with a honeycombed structure.
The voids in the film may be gas-filled, empty or filled with other materials to produce specific taste-burst
characteristics or to deliver active drugs. The light honeycombed structure results in capsules that dissolve
rapidly, causing a melt-in-the-mouth sensation. This revolutionary invention is also patented for SEPTUMdouble chamber capsules.

Partners in the revolution

The BioProgress business model is to establish long-term partnerships with
companies that have the skills, energy and vision to turn our unique technology
systems into successful consumer products.

A number of companies worldwide are evaluating the ways that they can use the unique patented XGelfilm systems to reduce product costs, extend product lifecycle and to develop exciting new products. Some
have already concluded agreements covering particular technologies, specific products or geographical areas.

FMC Biopolymer
FMC Biopolymer is headquartered in Philadelphia, Pennsylvania and has R & D, sales and manufacturing
facilities in the USA, Latin America, Asia and across Europe. It is one of the worlds leading suppliers of
formulation excipients to the pharmaceutical industry. FMC has signed agreements on NROBEsystems
which run until 2023. It has full responsibility for the commercialisation of NROBE BioProgress continues
to develop the XGelfilms and will be producing at least 50% of them until 2006. The sales value of a
minimum number of machines to be purchased from BioProgress in the first six years following commercialisation
is estimated to exceed $80m.
www.fmcbiopolymer.com


Grupo Famasierra
Farmasierra, located in Madrid, is one of Spains leading producers of pharmaceutical products. It has been
working with BioProgress for several years on various XGeltechnologies.
Farmasierra are FMCs exclusive manufacturer in Europe during the initial commercialisation of NROBE
They will also provide FMC with development facilities. The first production machines for NROBEwill be
delivered to Farmasierra in 2005.
www.farmasierra.com

Wyeth
Wyeths headquarters are based in New Jersey.
It is one of the leading global marketers of pharmaceutical and healthcare products. It has a turnover of $15.8bn
and sells its products in 140 countries.
Wyeth owns some of the best known consumer brands in the world, including Advil analgesics, Centrum and
Solgar vitamins, Robitussin cough products and Chap Stick.
Wyeth concluded an exclusive licensing option for XGeland SWOLLOliquid-fill capsule technology in June
2004 for certain specified fields.
A spokesman for Wyeth said We believe BioProgress has developed some interesting technology. We are
entering into this agreement to secure an exclusive position to enable a full detailed evaluation of the opportunity.
www.wyeth.com


Perrigo
Perrigo is the largest producer of label medicines and healthcare supplements in the USA, with a turnover of $898m.
The company is also a substantial contract pharmaceutical manufacturer. Perrigo supplies store brand to most
of Americas biggest pharmaceutical retailers, including Walmart, Walgreens and Safeway. Perrigo also has
manufacturing facilities located in the UK and Mexico. Perrigo concluded a global licensing agreement for
TABWRAPtechnology in March 2004 for a specific market sector. Perrigo has the option to set up
its own film facility for its own products and to supplement BioProgress film supply elsewhere.
www.perrigo.com


Harro-Hoefliger
Harro-Hoefliger GmbH, located near Stuttgart, is one of the worlds leading manufacturers of packaging
machinery and process technology for the pharmaceutical industry. Established in 1975, it has grown to a
turnover of 50m euros. Sales are split 55% in Europe and the remainder in the USA. In October, 2003
Hoefliger and BioProgress completed an agreement to work together on machine design for the XGeltechnologies. Hoefliger is building the first machines for delivery in 2005 and will become exclusive suppliers,
service and warranty providers to BioProgress and partners.
www.hofliger.com


A revolution in product development

Working from our purpose-built 25,000 sq ft research and development facilities
at March, Cambridgeshire, Bioprogress Special Services provides a resource to
any partner looking to create new products or improve existing ones.

To preserve confidentiality, partners may use one of the individual design pods where one of their staff and the
BioProgress technicians can work on company projects in a secure and private environment.

XGeltechnology can be used in a number of industries. To date most of the development work has been
with partners in the pharmaceutical and film industries. However, an increasing number of companies in other
industries have been excited by the possibilities that XGelfilm technology brings to their product development.


Micap
Micap plc signed an option agreement in 2004 to combine its expertise in micro encapsulation technology with
the BioProgress water-soluble films. The developments will be aimed at providing new delivery mechanisms for
the $1.4bn global market for smoking cessation products (SCPs).
www.micap.company.uk


Colgate-Palmolive
Colgate launched MaxFreshtoothpaste in the USA in August 2004. This revolutionary product contains
mini-breath strips incorporated within the toothpaste gel. The mini breath strips were developed and manufactured
BioTec Films LLC in Tampa, Florida. BioTec Films LLC is a wholly-owned subsidiary of BioProgress.
www.colgatemaxfresh.com


Convatec A Bristol-Myers Squibb Company
Bristol-Myers Squibb is a leading US healthcare company with a turnover of $20.9bn operating on a global scale.
Its Convatec division has a turnover of $843m, of which $512m is Ostomy products. These include products for
colostomy, ileostomy and urostomy. Bristol-Myers Squibb concluded an agreement in 2001 to become partners
with BioProgress in developing a revolutionary range of flushable and biodegradable Ostomy products.Central
to the product range is a bag, which when treated with a spray, may be safely flushed down the toilet system where
it disintegrates and is fully biodegradable. BioProgress patented this unique XGelsystem in 2001.
www.bms.com
www.convatec.com


The revolution continues

These are exciting times for BioProgress. After several years of formulating, developing and
Testing ranges of XGelfilms and XGelsystems, we are now seeing the first of these products reaching the
market. They will change forever the way that some products are manufactured and presented. They will bring
the consumer benefits and new choices. They will reduce production costs, and provide our customers with a
marketing advantage ahead of competitors still dedicated to old technologies.

The partnership system is creating new products, by matching the market and product knowledge of our
customers with the technical knowledge we have for the XGelfilms and their applications.

We welcome new partners who have the imagination, resources and skills to turn XGelfilms into novel and
revolutionary global products.

..

The revolution continues

Contacts:

BioProgress Technology Ltd
Alan Clements, Sales and Marketing Director
alanclements@bioprogress.com

Thomas Payne, Sales Support Manager
thomaspayne@bioprogress.com

Hostmoor Avenue, March,
Cambridgeshire, PE15 0AX, UK

Tel: +44 (0) 1354 655 674
Fax: +44 (0) 1354 655 858

www.bioprogress.com

BioTec Films LLC
Richard Fielder, Sales Manager
rfielder@biotecfilms.com

7455 Adamo Drive, Tampa
Florida, 33619, USA

Tel: (001) 813 628 0424
Fax: (001) 813 628 0162

very quiet on this, how come BPRG is stagnent whilst SEo is flying????

That's justice for you!

Always did think the court case was a bit of a red herring. Price action might well imply that now.

Please.... can management not give us some hope...even on the horizon.

What management?!!

SEO up another 3% today whilst BPRG down 1.5%

Why did I buy at 74.7p, with charges I need 80.2p to be in profit, anyway my others are in profit so heres keeping the faith that this will upturn sometime soon.

Yes SEO is up around 100% from losing the court battle.. BPRG is down around 50%
That says it all.